PTC Therapeutics (PTCT) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PTCT Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PTC Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$72.72 |
| 52 Week High | US$87.50 |
| 52 Week Low | US$43.18 |
| Beta | 0.53 |
| 1 Month Change | -0.40% |
| 3 Month Change | 4.71% |
| 1 Year Change | 60.49% |
| 3 Year Change | 25.10% |
| 5 Year Change | 85.56% |
| Change since IPO | 340.99% |
Recent News & Updates
Seeking Alpha • May 10
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage
Summary PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk. PTCT trades at a significant valuation discount to peers despite robust launch metrics, a durable cash runway, and a pipeline with multiple catalysts. Read the full article on Seeking Alpha
Narrative Update • May 03
PTCT: Early Neurology Launch And Huntington Progress Will Support Bullish 2026 Outlook
Analyst fair value for PTC Therapeutics has edged up by about $0.20 as analysts incorporate slightly less severe revenue declines, higher expected profitability, and a lower future P/E into their updated models following recent Q4 commentary and new coverage initiations. Analyst Commentary Street research on PTC Therapeutics over the past few months has centered on how Q4 results, early Sephience data, and franchise mix shape the earnings outlook and what that implies for fair value.Recent updates
Seeking Alpha • May 10
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage
Summary PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk. PTCT trades at a significant valuation discount to peers despite robust launch metrics, a durable cash runway, and a pipeline with multiple catalysts. Read the full article on Seeking AlphaNarrative Update • May 03
PTCT: Early Neurology Launch And Huntington Progress Will Support Bullish 2026 Outlook
Analyst fair value for PTC Therapeutics has edged up by about $0.20 as analysts incorporate slightly less severe revenue declines, higher expected profitability, and a lower future P/E into their updated models following recent Q4 commentary and new coverage initiations. Analyst Commentary Street research on PTC Therapeutics over the past few months has centered on how Q4 results, early Sephience data, and franchise mix shape the earnings outlook and what that implies for fair value.Narrative Update • Apr 19
PTCT: Early Neurology Launch And Pipeline Progress Will Support Bullish 2026 Outlook
Analysts have nudged their average price target for PTC Therapeutics higher to about $88 from roughly $86.50. This reflects updates to models after recent Q4 commentary, revised views on revenue trends, margin expectations, and future P/E assumptions.Narrative Update • Apr 05
PTCT: Early Neurology Launch Execution Will Drive Bullish 2026 Outlook
Narrative Update on PTC Therapeutics The analyst price target for PTC Therapeutics has been trimmed from $87.93 to $86.50 as analysts balance generally higher Street targets and improved profit margin assumptions with slightly softer revenue growth expectations and a more conservative future P/E. Analyst Commentary Recent research updates on PTC Therapeutics show a mix of optimism and caution, with several analysts adjusting price targets after the Q4 report, Sephience launch updates, and broader sector views.
Narrative Update • Mar 22
PTCT: Future Earnings Power Will Be Driven By Growing PKU And Huntington’s Pipelines
Analysts have raised PTC Therapeutics' consensus price target from the low $90s to around $120, citing updated Q4 results, early Sephience traction, and expectations that newer revenue streams could offset pressure in the DMD franchise. Analyst Commentary Recent research on PTC Therapeutics has leaned constructive, with several bullish analysts tying higher valuation ranges to execution around Sephience, updated Q4 commentary, and the broader revenue mix.Narrative Update • Mar 07
PTCT: Future Earnings Power Will Be Driven By Expanding PKU And Huntington’s Franchises
The analyst price target for PTC Therapeutics has been raised by $6.61, with analysts pointing to stronger modeled revenue growth, higher profit margins, and updated P/E assumptions following recent Q4 commentary and comparative advantages in Huntington's disease treatments. Analyst Commentary Recent Street research around PTC Therapeutics has been broadly constructive, with several bullish analysts adjusting their models after the Q4 update and early Sephience launch commentary.Narrative Update • Feb 21
PTCT: Sephience Execution Will Drive Bullish 2026 Outlook Despite DMD Pressure
Narrative Update: PTC Therapeutics The analyst price target for PTC Therapeutics has shifted modestly lower to align with our updated fair value of about $87.93, as analysts weigh mixed revisions to revenue growth and profitability assumptions against ongoing support from Sephience-driven estimates. Analyst Commentary Recent Street research on PTC Therapeutics centers on how Sephience trends could influence the company’s revenue mix, profitability path, and valuation, especially as the DMD franchise faces pressure.Narrative Update • Feb 06
PTCT: Index Additions And Pipeline Execution Will Shape Bullish 2026 Outlook
Analysts have raised their fair value estimate for PTC Therapeutics to about $88.50 from $81.86, reflecting updated views on the discount rate, revenue trends, profit expectations, and a higher assumed future P/E that aligns with recent price target increases from several research firms. Analyst Commentary Recent Street research on PTC Therapeutics has focused on price target adjustments and rating changes, which feed directly into how analysts think about valuation, execution risk, and potential growth opportunities.
Narrative Update • Jan 23
PTCT: Single-Drug Dependence Will Likely Limit Upside Despite Strong Launch Start
Narrative Update: PTC Therapeutics (PTCT) The analyst price target for PTC Therapeutics is updated in line with a series of upward Street revisions, as analysts point to stronger than expected Sephience launch metrics and recent Q3 outperformance, along with generally supportive views on small to mid cap biotech heading into 2026. Analyst Commentary Street research on PTC Therapeutics has leaned positive around the Q3 report and the Sephience launch, with several large firms lifting price targets after what they describe as strong initial commercial execution.Narrative Update • Jan 08
PTCT: Future Earnings Power Will Be Driven By Expanding PKU Franchise
The analyst price target for PTC Therapeutics has been raised from about $103 to about $115. Analysts cited stronger Sephience launch trends, a shift in the modeled profit margin to 34%, a more moderate future P/E near 20x, and a less conservative revenue outlook as key drivers of the change.Narrative Update • Dec 25
PTCT Overreliance On Single Drug Will Likely Cap Share Price Upside
The analyst fair value estimate for PTC Therapeutics has been raised from $44.00 to $55.00 per share as analysts factor in stronger than expected Sephience launch metrics, upwardly revised price targets across the Street, and improving confidence in the durability of the company’s growth trajectory. Analyst Commentary Recent Street research has broadly welcomed PTC Therapeutics Q3 performance and the stronger than expected Sephience launch, with several major firms lifting their price targets.Narrative Update • Dec 11
PTCT: Launch Momentum And Index Additions Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by about $1.36 to roughly $81.86, as analysts highlight stronger than expected Sephience launch metrics, improving revenue and margin assumptions, and sustained post earnings momentum. Analyst Commentary Analysts are broadly constructive on PTC Therapeutics following its latest earnings, citing Sephience outperformance and improving visibility into the company’s growth trajectory.Narrative Update • Nov 27
PTCT: Revenue Outlook And New Launch Performance Will Influence 2025 Assessment
Analysts have raised their price target for PTC Therapeutics from approximately $77.93 to $80.50, citing stronger-than-expected Sephience sales and continued momentum following the company's latest earnings report. Analyst Commentary Recent reports from Wall Street analysts reflect a range of views regarding PTC Therapeutics' execution and growth prospects, primarily driven by the company's strong recent earnings and the launch of Sephience.Narrative Update • Nov 11
PTCT: Revenue Guidance Narrowing And Launch Momentum Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by $10, as analysts cite stronger-than-expected Sephience sales and increasing momentum following the company's recent earnings beat. Analyst Commentary Recent analyst reports on PTC Therapeutics highlight a wide range of perspectives following the company’s robust third-quarter results and new product launches.Narrative Update • Oct 28
Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
Analysts have increased their average price target for PTC Therapeutics by approximately $1.25 to $67.93. They cite heightened community interest in Sephience, improved profit margin forecasts, and overall strong sentiment for upcoming launches, despite recent regulatory setbacks.Analysis Article • Sep 08
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Shares Bounce 26% But Its Business Still Trails The Industry
PTC Therapeutics, Inc. ( NASDAQ:PTCT ) shares have had a really impressive month, gaining 26% after a shaky period...Narrative Update • Aug 27
Broad Approvals Will Elevate Rare Disease Markets Despite Setbacks
Analysts lowered their price targets for PTC Therapeutics following the FDA's Complete Response Letter for vatiquinone, citing the removal of Friedreich's ataxia revenues and increased regulatory uncertainty, though encouraging early signals from the Sephience launch and its broad approval label partially offset downside, resulting in a modest consensus target reduction from $68.31 to $66.69. Analyst Commentary Bullish analysts highlight the recent selloff post-FDA Complete Response Letter (CRL) for vatiquinone in Friedreich's ataxia as a buying opportunity, believing negative outcomes were anticipated and already priced into shares.
New Narrative • Mar 21
2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs
Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues.Seeking Alpha • Mar 09
PTC Therapeutics: Upside In Rare Disease Innovation
Summary PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over $2 billion, providing a buffer as it awaits regulatory approvals to boost revenue. PTC's diversified pipeline, including vatiquinone for Friedreich's ataxia, could significantly enhance revenue if approved, targeting a $2.8 billion market. Financial risks remain due to reliance on regulatory outcomes and high R&D spending, but Evrysdi royalties offer some revenue stability. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
Summary PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza, amid regulatory challenges and generic competition. Despite a strong cash position, PTC's heavy losses and uncertain pipeline prospects justify maintaining a "sell" rating. Upcoming catalysts in 2025, including FDA decisions on Translarna and sepiapterin, are critical but uncertain. Competitive pressures in the DMD market and doubts about pipeline drugs' market potential further support a cautious outlook. Read the full article on Seeking AlphaShareholder Returns
| PTCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.8% | 1.0% | 1.1% |
| 1Y | 60.5% | 40.3% | 26.7% |
Return vs Industry: PTCT exceeded the US Biotechs industry which returned 44.4% over the past year.
Return vs Market: PTCT exceeded the US Market which returned 25.4% over the past year.
Price Volatility
| PTCT volatility | |
|---|---|
| PTCT Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PTCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PTCT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 991 | Matt Klein | www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia.
PTC Therapeutics, Inc. Fundamentals Summary
| PTCT fundamental statistics | |
|---|---|
| Market cap | US$6.09b |
| Earnings (TTM) | -US$186.73m |
| Revenue (TTM) | US$827.11m |
7.3x
P/S Ratio-32.3x
P/E RatioIs PTCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTCT income statement (TTM) | |
|---|---|
| Revenue | US$827.11m |
| Cost of Revenue | US$520.69m |
| Gross Profit | US$306.42m |
| Other Expenses | US$493.14m |
| Earnings | -US$186.73m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.25 |
| Gross Margin | 37.05% |
| Net Profit Margin | -22.58% |
| Debt/Equity Ratio | -1,448.6% |
How did PTCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 06:04 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PTC Therapeutics, Inc. is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Herrmann | Baird |
| Joel Beatty | Baird |
| null null | Baird |